Adjustable Quarto Stimuli (T, pH, Redox, Hyperthermia) Targeted Nanocontainers (Nano4Dox and Nano4Cis) for Cancer Therapy Based on Trojan Horse Approach

We developed a quadrupole stimuli responsive targeted nanomedicine platform with the key goal to provide a solution to the outstanding problem “How can the delivered therapeutic dose to the tumour be increased while at the same time reducing the dose in healthy tissue?” When accomplishing this goal, we will offer a huge improvement in the length and quality of life of cancer patients. Our preliminary animal study give hope in that course. We attempted to accomplish this goal via an innovative and patented therapeutic approach based on novel polymeric nanocarriers (NCs), which enables targeted drug delivery in tumors. The in-vivo results suggest that both Nano4Dox and Nano4Cis platforms outperforms the commercial standards like Doxil® and Lipoplatin, respectively. These platforms offer a significant business opportunity besides the therapeutic value offering to millions of people hope for better life and cure. This work is licensed under Creative Commons Attribution 4.0 License APPR.MS.ID.000501. Archives of Pharmacy & Pharmacology Research Volume 1-Issue 1 Citation: George K. Adjustable Quarto Stimuli (T, pH, Redox, Hyperthermia) Targeted Nanocontainers (Nano4Dox and Nano4Cis) for Cancer Therapy Based on Trojan Horse Approach. Arch Phar & Pharmacol Res. 1(1): 2018. APPR.MS.ID.000501. Page 2 of 7 targeting pathological tissue, inducing localised drug release. This technology leverages the fact that tumors (as well as other types of diseased tissue) are known to have specific extracellular environments with lower pH, higher temperature and/ or enhanced glutathione levels compared to healthy tissues. Furthermore, the Nano4XX platforms are grafted with targeting groups e.g. folic acid for breast cancer, leuprolide for prostate cancer, etc. The Nano4XX platforms are designed such to become unstable specifically under the conditions present in cancer, the release of the encapsulated compounds is directed at the target tissue. As such, encapsulating drugs in our Nano4XX has a beneficial effect on the accumulating dose in target tissue and thus the intended effect of the drug as well as on unwanted side-effects on healthy tissues. The Nano4XX platforms integrate four stimuli, namely pH, temperature (T), reducing environments (glutathione) and alternating magnetic fields (Figure 1). Loading and release studies with anthracycline antibiotics confirm the high loading capacity of the NCs along with the sensitive response to any needed combination of stimuli. Figure 1: Principle of the Nano4XX platform. We have observed in vivo and in vitro evidence of the functional added value of our proprietary [20] Nano4XX for the delivery of anti-tumour and antibacterial drugs. Furthermore, we have a strong IP position and developed a business plan that describes the optimal route-to-market for our technology [21]. Just to mention the business opportunity of our system, the doxorubicin global market volume was USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024, according to a new report by Grand View Research, Inc. [22]. If our system passes clinical trial, we will provide first a safe delivery of drugs to tumors and second a great business opportunity. Because we can load in our Nano4XX platform any commercial drug, our technology presents the business potential accordingly multiplied by the market value of each drug. A business revolution in cancer therapy.